Global Enalapril Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Enalapril Market Research Report 2024
Enalapril is used to treat hypertension, symptomatic heart failure, and asymptomatic left ventricular dysfunction.[9] It has been proven to protect the function of the kidneys in hypertension, heart failure, and diabetes, and may be used in the absence of hypertension for its kidney protective effects.[10] It is widely used in chronic kidney failure.[11] Furthermore, enalapril is an emerging treatment for psychogenic polydipsia.
According to Mr Accuracy reports’s new survey, global Enalapril market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Enalapril market research.
Key manufacturers engaged in the Enalapril industry include Apotex Inc, Apothecon Inc Div Bristol Myers Squibb, Ivax Pharmaceuticals Inc Sub Teva Pharmaceuticals Usa, Krka Dd Novo Mesto, Lek Pharmaceuticals D D, Mylan Pharmaceuticals Inc, Ranbaxy Laboratories Ltd, Sandoz Inc and Taro Pharmaceutical Industries Ltd, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Enalapril were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Enalapril market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Enalapril market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Apotex Inc
Apothecon Inc Div Bristol Myers Squibb
Ivax Pharmaceuticals Inc Sub Teva Pharmaceuticals Usa
Krka Dd Novo Mesto
Lek Pharmaceuticals D D
Mylan Pharmaceuticals Inc
Ranbaxy Laboratories Ltd
Sandoz Inc
Taro Pharmaceutical Industries Ltd
Teva Pharmaceuticals Usa Inc
Watson Laboratories Inc
Wockhardt Americas Inc
Biovail Laboratories International Srl
Bedford Laboratories Div Ben Venue Laboratories Inc
Hikma Farmaceutica (Portugal) Sa
Hospira Inc
Teva Parenteral Medicines Inc
Segment by Type
2.5mg
5mg
10mg
20mg
Hospital
Drugs Store
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Enalapril report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Enalapril market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Enalapril market research.
Key manufacturers engaged in the Enalapril industry include Apotex Inc, Apothecon Inc Div Bristol Myers Squibb, Ivax Pharmaceuticals Inc Sub Teva Pharmaceuticals Usa, Krka Dd Novo Mesto, Lek Pharmaceuticals D D, Mylan Pharmaceuticals Inc, Ranbaxy Laboratories Ltd, Sandoz Inc and Taro Pharmaceutical Industries Ltd, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Enalapril were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Enalapril market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Enalapril market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Apotex Inc
Apothecon Inc Div Bristol Myers Squibb
Ivax Pharmaceuticals Inc Sub Teva Pharmaceuticals Usa
Krka Dd Novo Mesto
Lek Pharmaceuticals D D
Mylan Pharmaceuticals Inc
Ranbaxy Laboratories Ltd
Sandoz Inc
Taro Pharmaceutical Industries Ltd
Teva Pharmaceuticals Usa Inc
Watson Laboratories Inc
Wockhardt Americas Inc
Biovail Laboratories International Srl
Bedford Laboratories Div Ben Venue Laboratories Inc
Hikma Farmaceutica (Portugal) Sa
Hospira Inc
Teva Parenteral Medicines Inc
Segment by Type
2.5mg
5mg
10mg
20mg
Segment by Application
Hospital
Drugs Store
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Enalapril report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source